Pulmonary tuberculosis: Difference between revisions

From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations")
No edit summary
Line 43: Line 43:
 
[[Category:Respiratory infections]]
 
[[Category:Respiratory infections]]
 
[[Category:Tuberculosis]]
 
[[Category:Tuberculosis]]
[[Category:Mycobacteria]]
 

Revision as of 15:55, 20 August 2020

Background

Microbiology

Clinical Manifestations

  • Presents as reactivation of latent infection months or years after primary tuberculosis
  • Subacute or chronic cough (at least 2 to 3 weeks) eventually becoming productive and occasionally involving hemoptysis
    • Should be suspected in any patient with cough and HIV infection
  • Constitutional symptoms, with fevers, night sweats, and unexplained weight loss
  • Usually from reactivation of latent tuberculosis infection, and usually reactivates in lung apices
  • May transiently improve with partially-active antibiotics such as fluoroquinolones

Investigations

  • Spontaneous sputum, induced sputum, or bronchoalveolar lavage specimens should be sent for
    • Acid-fast staining of a smear
    • Culture
    • PCR

Management

  • Empiric treatment for suspected drug-susceptible tuberculosis is RIPE x2mo then RI x4mo
    • Isoniazid 5mg/kg/d, max 300mg daily, with pyridoxine 25 mg po daily
    • Rifampin 10mg/kg/d
    • Pyrazinamide 25mg/kg/d, max 2g daily
    • Ethambutol 20mg/kg/d, max 1.2g daily, which can be dropped once susceptibility testing shows that it is pan-susceptible
  • Standard duration for uncomplicated disease is 6 months total, though it is extended if high risk of relapse (see below)
  • Treatment for multidrug-resistant tuberculosis is discussed separately

Special populations

  • For the elderly, or those at elevated risk of hepatotoxicity: can do induction phase without pyrazinamide and extend continuation phase to 7 months (from 4)
  • For pregnant women: can consider dropping pyrazinamide and extending the course by 3 months, but if there is severe disease then likely should follow standard treatment
  • For high risk of relapse, including extensive or cavitary disease in the first 2 months of treatment, culture-positivity after 2 months of treatment, or cavitary disease on CXR at end of treatment: the consolidation phase should be extended by 3 months (to 9 months total treatment)
  • For severe liver disease:

Infection control

  • Airborne precautions until:
    • Treated for at least 2 weeks and symptoms are clearly improving
    • 3x negative sputum smears
    • They can be discharged home when clinical improvement, drug-resistant TB is not suspected and there is no contraindication for home isolation